Table 3.
Change scores for exploratory outcomes, including cardiovascular risk factors and factors related to the primary and secondary trial outcomes
| Intermittent fasting | Ad libitum control | P-value | |
|---|---|---|---|
| Changes in the lipid profile | |||
| Total cholesterol (mg/dL) | 1.21 ± 19.6 | 3.91 ± 19.6 | 0.57 |
| HDL-C (mg/dL) | 2.37 ± 6.20 | −0.39 ± 5.17 | 0.05 |
| Triglycerides (mg/dL) | −6.8 ± 51.9 | 12.4 ± 46.6 | 0.11 |
| Non-HDL-C (mg/dL) | 0.47 ± 16.6 | 4.30 ± 18.6 | 0.36 |
| Apolipoprotein B (mg/dL) | 0.21 ± 41.4 | −5.73 ± 34.4 | 0.29 |
| Changes in the metabolism | |||
| Fasting glucose (mg/dL) | −7.21 ± 9.30 | −2.12 ± 11.1 | 0.04 |
| Fasting insulin (mIU/L) | −2.76 ± 2.61 | −0.33 ± 3.51 | 0.001a |
| Changes in blood pressure and inflammation | |||
| Systolic blood pressure (mmHg) | −3.3 ± 12.2 | 0.0 ± 16.4 | 0.33 |
| Diastolic blood pressure (mmHg) | −1.7 ± 9.1 | 4.9 ± 11.8 | 0.01 |
| hsCRP (mg/L) | 1.02 ± 2.73 | −0.25 ± 5.66 | 0.23 |
| Changes in other MicroCog factors | |||
| GCFi score | 1.86 ± 7.09 | 2.97 ± 5.49 | 0.48 |
| Changes in anthropometrics | |||
| Weight (kg) | −1.70 ± 4.69 | 0.20 ± 3.45 | 0.06 |
| Waist circumference (cm) | −2.88 ± 11.47 | −0.35 ± 4.41 | 0.40 |
GCFi, general cognitive functioning index; HDL-C, high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reaction protein.
a
Significant at P < 0.0028 when corrected for 18 comparisons (the primary outcome, 4 secondary outcomes, and the 13 outcomes in the table).